AbbVie says new Mavyret data to be presented at AASLD meeting
AbbVie announced that it will present new data evaluating Mavyret, its once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus infection across all major genotypes at the annual meeting of the American Association for the Study of Liver Diseases, or AASLD. Sixteen AbbVie scientific abstracts have been accepted, including two oral presentations studying the use of Mavyret in patients across genotypes with compensated cirrhosis and treatment-naive patients with genotype 3 HCV. These populations have historically had limited treatment options. A third oral presentation evaluates adherence to treatment with Mavyret in the clinical development program. The Liver Meeting will take place from October 20-24.